CAR-T对比历史对照改善复发难治大B细胞淋巴瘤生存与医疗资源使用
加拿大真实世界研究采用倾向加权分析,比较复发难治大B细胞淋巴瘤患者接受CAR-T(n=85)与符合现行标准的历史对照(n=150)的3年生存与医疗资源使用。CAR-T组3年总生存59% vs 10%,无进展生存48% vs 6%,风险比分别为0.21和0.28,且住院、急诊、ICU及发热/感染/中性粒细胞减少相关住院率均更低。
要点
- CAR-T组3年OS 59%、PFS 48%,历史对照仅10%和6%。
- CAR-T对比历史对照OS风险比0.21、PFS风险比0.28。
- CAR-T组住院、急诊、ICU及感染相关住院率均更低。
核心结论
- CAR-T在复发难治大B细胞淋巴瘤中产生持续生存获益并减少医疗资源使用。
- 尽管CAR-T毒性明确,历史对照的住院事件更多,反映缺乏有效挽救治疗。
研究设计与样本
- 倾向加权分析比较CAR-T组(n=85)与CAR-T获批前符合现行标准的历史对照(n=150)。
- 比较3年生存、医疗资源使用和住院事件。
主要发现
- CAR-T 3年OS为59%(95%CI 42-72;中位未达到),历史对照为10%(95%CI 5-16;中位4.4个月)。
- CAR-T 3年PFS为48%(95%CI 32-63;中位14.4个月),历史对照为6%(95%CI 3-11;中位3.6个月)。
- CAR-T对比历史对照OS风险比0.21(95%CI 0.14-0.31),PFS风险比0.28(95%CI 0.2-0.39)。
- 每1000人日风险,CAR-T组住院5.32 vs 9.1、急诊2.33 vs 4.81、ICU 0.53 vs 1.25。
- CAR-T组发热(0.93 vs 1.63)、感染(1.48 vs 3.08)、中性粒细胞减少(0.66 vs 1.97)住院率更低,均P<.001。
临床怎么用
- 对于符合现行标准的复发难治大B细胞淋巴瘤患者,CAR-T较历史挽救治疗显著改善生存。
- CAR-T虽存在毒性,但整体住院事件少于历史对照,支持其作为有效治疗选择。
局限性
- 为真实世界非随机比较,采用倾向加权分析控制混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapies have been funded in Canada for relapsed/refractory large B-cell lymphoma (R/R-LBCL) after 2 lines of systemic therapy since late 2019. Real-world outcome data have been limited by lack of comparison to historical care. Using propensity-weighted analysis, we compared 3-year survival, health care resource use (HRU), and hospitalization events for patients with R/R-LBCL treated with CAR-T (n = 85) vs historical controls (HCs) treated before CAR-T approval who would have been eligible based on present criteria (n = 150). CAR-T 3-year overall survival (OS) was 59% (95% confidence interval [CI], 42-72; median, not reached) vs 10% (95% CI, 5-16; median, 4.4 months) in HCs. Three-year CAR-T progression-free survival (PFS) was 48% (95% CI, 32-63]; median, 14.4 months) vs 6% (95% CI, 3-11; median, 3.6 months) in HCs. The hazard ratio (HR) for OS was 0.21 (95% CI, 0.14-0.31), and for PFS was 0.28 (95% CI, 0.2-0.39), comparing CAR-T vs HCs. Per 1000 person-days at risk, patients receiving CAR-T had fewer hospital admissions than HCs (5.32 vs 9.1), emergency visits (2.33 vs 4.81), and intensive care admissions (0.53 vs 1.25), plus lower hospitalization rates for fever (0.93 vs 1.63), infection (1.48 vs 3.08), and neutropenia (0.66 vs 1.97; all P< .001). CAR-T produced a sustained survival benefit, and, despite well-described CAR-T toxicities, HCs experienced more hospitalization events, underscoring the lack of effective salvage treatments. As one of the largest real-world comparisons of patients with R/R-LBCL receiving CAR-T vs previous standard of care, this study demonstrated its improved effectiveness and reduced HRU.
引用
- Kordbacheh T, Chan KKW, Crump M, et al. Improved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma. Blood Adv. 2026. PMID: 41544221. doi:10.1182/bloodadvances.2025017401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。